David

I hear you loud and clear. My MO is equally puzzled. I think the discussion in one thread is the best but saddest answer: unlike Erbitux, there is no big money to be made by doing extensive clinical studies so as to sell more of an incredibly expensive drug like Erbitux instead of plain old relatively inexpensive carboplatin. One reason I like my CCC is that they are always on the cutting edge, as shown by the recent OCF news feed on their growing little tumors of patients to try out multiple drugs. They also are part of the NIH experimental TIL study that was my fallback position.
I'm off to my carboplatin infusion in an hour since they are confident enough to use carbo instead of cis, again based on actual patient results
Charm